Nitrosamine Testing for Metformin and Oral Hypoglycemics: A Complete CRO Service Overview
Introduction: Nitrosamine testing for metformin is no longer optional — it is a regulatory and patient safety requirement that every […]
Lifecycle Management Strategies for Dexamethasone Injectables
Introduction: Lifecycle management strategies for dexamethasone injectables are essential for pharmaceutical manufacturers aiming to sustain product relevance, regulatory compliance, and
Lifecycle Management Strategies for Dexamethasone Injectables Read More »
Method Validation for Extractables and Leachables Testing: What ICH Q2(R2) Requires
Introduction: Method validation for extractables and leachables testing is a regulatory non-negotiable — without a fully documented, ICH Q2(R2)-compliant validation
Method Validation for Extractables and Leachables Testing: What ICH Q2(R2) Requires Read More »
Multi-Attribute Monitoring (MAM) for Therapeutic Peptide Characterization: A Modern LC-MS Workflow
Multi-Attribute Monitoring (MAM) for Therapeutic Peptide Characterization: A Modern LC-MS Workflow Introduction Liquid chromatography-mass spectrometry (LC-MS)-based Multi-Attribute Monitoring (MAM) has
Case Study: Developing a Receptor-Targeted Peptide Oligonucleotide Conjugate for Muscle Delivery in Duchenne Muscular Dystrophy
Introduction: A receptor-targeted peptide oligonucleotide conjugate (POC) is an engineered biotherapeutic that links an antisense oligonucleotide (ASO) payload to a
Regulatory Expectations for Peptide-Oligonucleotide Conjugates in IND Submissions
Introduction to Regulatory Expectations for Peptide-Oligonucleotide Conjugates in IND Submissions The regulatory pathway for advancing Peptide-Oligonucleotide Conjugates (POCs) in Investigational
Regulatory Expectations for Peptide-Oligonucleotide Conjugates in IND Submissions Read More »
Immunogenicity Assessment in Biosimilar Development: Regulatory Strategy and Testing Approaches
Introduction: Why Immunogenicity Assessment in Biosimilar Development Is Non-Negotiable Immunogenicity assessment in biosimilar development refers to the structured process of
Extractables & Leachables (E&L) Testing Services for Prefilled Syringe Drug Products
Introduction How Does a Comprehensive E&L Program Mitigate Risk in Prefilled Syringe Development? A comprehensive Extractables & Leachables (E&L) program
Extractables & Leachables (E&L) Testing Services for Prefilled Syringe Drug Products Read More »
Cell Line Development for Biosimilars: Choosing the Right Expression System and Clone Selection Strategy
Introduction to Biosimilar Cell Line Engineering In the biopharmaceutical industry, Cell Line Development for Biosimilars is a highly regulated, comparability-driven
Mass Spectrometry Workflows for Structural Characterization of Peptide Oligonucleotide Conjugates
Introduction The successful clinical development and regulatory approval of hybrid biotherapeutics depend on advanced analytical strategies for the Structural Characterization